Welgene Biotech Co., Ltd.(TW:6661)
NT$16.000.00 (0.00%)
TW:6661
Welgene Biotech Co., Ltd. financials statements
NT$16.00
At close:0.00 (0.00%)
Welgene Biotech Co., Ltd. (6661) Ratios
Welgene Biotech Co., Ltd. Ratios
TW:6661's free cash flow for Q2 2026 was NT$-58.44M. For the 2026 fiscal year, TW:6661's free cash flow was decreased by NT$-66.08M and operating cash flow was NT$7.64M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.21 | 2.34 | 2.39 | 2.89 | 2.99 |
| Quick Ratio | 1.98 | 2.07 | 1.97 | 2.56 | 2.75 |
| Cash Ratio | 1.37 | 1.27 | 1.47 | 1.51 | 1.75 |
| Solvency Ratio | 0.09 | 0.13 | 0.10 | 0.22 | 0.29 |
| Operating Cash Flow Ratio | 0.21 | 0.41 | -0.00 | 0.49 | 0.10 |
| Short-Term Operating Cash Flow Coverage | 0.88 | 2.71 | -0.02 | 4.59 | 0.90 |
| Net Current Asset Value | NT$ 27.71M | NT$ 87.72M | NT$ 58.38M | NT$ 170.44M | NT$ 226.66M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.36 | 0.25 | 0.28 | 0.12 | 0.06 |
| Debt-to-Equity Ratio | 0.80 | 0.45 | 0.53 | 0.17 | 0.08 |
| Debt-to-Capital Ratio | 0.45 | 0.31 | 0.35 | 0.14 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.33 | 0.25 | 0.27 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.21 | 1.83 | 1.88 | 1.43 | 1.37 |
| Debt Service Coverage Ratio | 0.64 | 1.37 | 1.08 | 2.75 | 2.79 |
| Interest Coverage Ratio | 0.04 | -0.24 | -1.63 | 59.12 | 28.64 |
| Debt to Market Cap | 0.42 | 0.21 | 0.24 | 0.02 | 0.02 |
| Interest Debt Per Share | 9.85 | 5.70 | 6.74 | 2.21 | 1.05 |
| Net Debt to EBITDA | -0.00 | -1.32 | -1.26 | -3.01 | -4.50 |
| Profitability Margins | |||||
| Gross Profit Margin | 34.39% | 42.11% | 42.67% | 44.05% | 42.62% |
| EBIT Margin | 0.03% | 1.31% | -0.15% | 4.30% | 5.44% |
| EBITDA Margin | 7.43% | 10.23% | 9.57% | 11.08% | 12.51% |
| Operating Profit Margin | 0.03% | -0.22% | -1.52% | 5.16% | 3.89% |
| Pretax Profit Margin | 0.36% | 0.39% | -1.08% | 4.21% | 5.31% |
| Net Profit Margin | 0.35% | 0.34% | -0.94% | 2.97% | 4.38% |
| Continuous Operations Profit Margin | 0.34% | 0.22% | -1.12% | 2.96% | 5.31% |
| Net Income Per EBT | 99.40% | 88.56% | 87.34% | 70.49% | 82.57% |
| EBT Per EBIT | 1053.54% | -177.56% | 71.19% | 81.57% | 136.33% |
| Return on Assets (ROA) | 0.21% | 0.21% | -0.48% | 2.19% | 3.23% |
| Return on Equity (ROE) | 0.47% | 0.38% | -0.91% | 3.14% | 4.42% |
| Return on Capital Employed (ROCE) | 0.03% | -0.18% | -1.01% | 5.02% | 3.92% |
| Return on Invested Capital (ROIC) | 0.02% | -0.09% | -0.93% | 3.29% | 3.01% |
| Return on Tangible Assets | 0.21% | 0.21% | -0.48% | 2.20% | 3.24% |
| Earnings Yield | 0.31% | 0.20% | -0.51% | 1.85% | 2.43% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.82 | 7.03 | 5.59 | 6.80 | 3.66 |
| Payables Turnover | 9.80 | 11.04 | 9.26 | 9.48 | 14.32 |
| Inventory Turnover | 6.31 | 5.06 | 2.99 | 5.30 | 6.65 |
| Fixed Asset Turnover | 1.60 | 1.84 | 1.41 | 3.89 | 9.82 |
| Asset Turnover | 0.60 | 0.61 | 0.51 | 0.74 | 0.74 |
| Working Capital Turnover Ratio | 1.96 | 1.78 | 1.49 | 1.52 | 1.58 |
| Cash Conversion Cycle | 67.28 | 90.97 | 147.94 | 84.03 | 129.03 |
| Days of Sales Outstanding | 46.69 | 51.93 | 65.35 | 53.65 | 99.59 |
| Days of Inventory Outstanding | 57.83 | 72.09 | 122.03 | 68.87 | 54.92 |
| Days of Payables Outstanding | 37.24 | 33.05 | 39.43 | 38.49 | 25.49 |
| Operating Cycle | 104.52 | 124.02 | 187.37 | 122.52 | 154.52 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.51 | 2.41 | -0.02 | 2.21 | 0.49 |
| Free Cash Flow Per Share | -0.26 | 2.20 | -1.21 | 1.05 | 0.30 |
| Dividend Paid and CapEx Coverage Ratio | 0.85 | 11.67 | -0.01 | 1.35 | 0.37 |
| Capital Expenditure Coverage Ratio | 0.85 | 11.67 | -0.01 | 1.91 | 2.57 |
| Operating Cash Flow Coverage Ratio | 0.16 | 0.43 | -0.00 | 1.00 | 0.47 |
| Operating Cash Flow to Sales Ratio | 0.09 | 0.17 | -0.00 | 0.16 | 0.04 |
| Free Cash Flow Yield | -1.40% | 9.24% | -5.40% | 4.75% | 1.22% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 325.74 | 498.95 | -203.18 | 54.15 | 41.44 |
| Price-to-Sales (P/S) Ratio | 1.15 | 1.72 | 1.86 | 1.61 | 1.81 |
| Price-to-Book (P/B) Ratio | 1.54 | 1.93 | 1.78 | 1.70 | 1.82 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -71.35 | 10.82 | -18.54 | 21.06 | 82.17 |
| Price-to-Operating Cash Flow Ratio | 12.29 | 9.89 | -1423.07 | 10.06 | 50.19 |
| Price-to-Earnings Growth (PEG) Ratio | 16.53 | -3.48 | 1.60 | -1.77 | -0.70 |
| Enterprise Value Multiple | 15.53 | 15.48 | 18.15 | 11.50 | 9.93 |
| Enterprise Value | 433.45M | 510.97M | 487.06M | 409.95M | 388.55M |
| EV to EBITDA | 15.53 | 15.48 | 18.15 | 11.50 | 9.93 |
| EV to Sales | 1.15 | 1.58 | 1.74 | 1.27 | 1.24 |
| EV to Free Cash Flow | -71.35 | 9.97 | -17.33 | 16.69 | 56.56 |
| EV to Operating Cash Flow | 12.29 | 9.11 | -1330.77 | 7.97 | 34.55 |
| Tangible Book Value Per Share | 12.25 | 12.68 | 12.87 | 13.01 | 13.38 |
| Shareholders’ Equity Per Share | 12.07 | 12.35 | 12.53 | 13.03 | 13.42 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | 0.44 | -0.04 | 0.30 | 0.17 |
| Revenue Per Share | 16.13 | 13.84 | 12.04 | 13.81 | 13.54 |
| Net Income Per Share | 0.06 | 0.05 | -0.11 | 0.41 | 0.59 |
| Tax Burden | 0.99 | 0.89 | 0.87 | 0.70 | 0.83 |
| Interest Burden | 10.54 | 0.30 | 7.31 | 0.98 | 0.98 |
| Research & Development to Revenue | 0.07 | 0.08 | 0.09 | 0.07 | 0.07 |
| SG&A to Revenue | 0.34 | 0.34 | 0.36 | 0.32 | 0.31 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 26.52 | 44.86 | 0.12 | 3.80 | 0.68 |
Currency in TWD
